Sugi Predict

Sugi Predict / Compounds / SCHEMBL254441

SCHEMBL254441

SCHEMBL254441

Cc1cccc(-n2cccn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ NOTUM Q6P988 1/20 0.48
▸ LMNA P02545 2/20 0.47
▸ GRM5 P41594 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 5/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ ERCC1 P07992 1/20 0.44
▸ ERCC4 Q92889 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.43
▸ MGLL Q99685 1/20 0.43
▸ KAT6A Q92794 2/20 0.42
▸ RXRA P19793 1/20 0.42
▸ GRIN1 Q05586 1/20 0.42
▸ GRIN2B Q13224 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29635610 1.00 TP53 (0.49) TP53KMT2AMEN1NOTUMLMNA
SCHEMBL5934873 0.86 NOTUM (0.57) KMT2AMEN1NOTUMLMNAGRM5
Hydrochloric Acid SCHEMBL6006151 0.84 NOTUM (0.55) KMT2AMEN1NOTUMLMNAGRM5
SCHEMBL14964128 0.82 MAPT (0.49) TP53KMT2AMEN1NOTUMLMNA
SCHEMBL873113 0.82 MAPT (0.53) TP53KMT2AMEN1NOTUMLMNA
SCHEMBL29635591 0.78 NOTUM (0.63) NOTUMLMNAMAPTALDH1A1KDM4E
SCHEMBL254803 0.78 NOTUM (0.63) NOTUMLMNAMAPTALDH1A1KDM4E
SCHEMBL82721 0.78 NOTUM (0.64) TP53KMT2AMEN1NOTUMGRM5
SCHEMBL14960622 0.77 ERCC1 (0.46) TP53KMT2AMEN1NOTUMLMNA
SCHEMBL2463180 0.77 NOTUM (0.48) KMT2AMEN1NOTUMLMNAGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247596-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS Natco Pharma Limited (IN) 2010-11-10 — — EP claimed
WO-2009098715-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS NATCO PHARMA LIMITED (IN) 2009-08-13 — — WO claimed
WO-2000018741-A2 PYRAZOLE COMPOUNDS AS COX-2 INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-06 — — WO claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS — 1998-12-30 — — WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 — — WO claimed
EP-4694893-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME Therapeutics LLC (US) 2026-02-18 — — EP disclosed
WO-2024229253-A1 METHODS AND TREATMENT OF VIRAL INFECTION CAUSED BY SARS-COV-2 WITH FUSED BICYCLIC HETEROCYCLIC COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2024-11-07 — — WO disclosed
WO-2024216229-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2024-10-17 — — WO disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 — — US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 — — US disclosed
US-6613747-B2 Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-02 — — US disclosed
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-01-16 — — US disclosed
US-6472372-B1 6-O-Carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICALS, INC. 2002-10-29 — — US disclosed
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-08-22 — — US disclosed
WO-2000018741-A2 PYRAZOLE COMPOUNDS AS COX-2 INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-06 — — WO disclosed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS — 1998-12-30 — — WO disclosed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 — — WO disclosed
US-4981516-A POLYOXYALKYLENE ETHER-MODIFIED MILLIKEN RESEARCH CORPORATION (US) 1991-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TP53 4634/4885KMT2A 2234/4885MEN1 4127/4885
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 TP53 949/4885KMT2A 359/4885MEN1 431/4885
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS Q6ZSR9, KDM4E, HK1 TP53 4727/4885KMT2A 673/4885MEN1 4129/4885
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials Q6ZSR9, HK1, KDM4E TP53 4767/4885KMT2A 657/4885MEN1 3933/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 TP53 4877/4885KMT2A 1615/4885MEN1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.